Nano composite emulsion for sustained drug release and improved bioavailability

Pharmaceutical Research

Volumn 31, Issue 10, 2014, Pages 2774-2783

  Sun, Wenqiang ^a   Ma, Xinrui ^a   Wei, Xiaohui ^a   Xu, Yuhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

cyclosporin A; nano composite emulsion; oral bioavailability; physical stability; poorly soluble drugs

Indexed keywords

CYCLOSPORIN; DRUG CARRIER; EMULSION; NANOCOMPOSITE; POLY(METHYL METHACRYLATE); SILICON DIOXIDE;

ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; BODY FLUID; CHEMISTRY; DRUG RELEASE; DRUG STABILITY; EMULSION; MALE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BODY FLUIDS; CYCLOSPORINE; DRUG CARRIERS; DRUG LIBERATION; DRUG STABILITY; EMULSIONS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NANOCOMPOSITES; POLYMETHYL METHACRYLATE; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SURFACE PROPERTIES;

EID: 84931073253     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1374-7     Document Type: Article

References (39)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.
2. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharm Sci Technol Today. 2000;4:138-45.
3. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2013;65(6):880-90.
4. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;1:91-7.
5. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;1:3-19.
6. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;6:734-46.
7. Strachan EB. Case report - suspected anaphylactic reaction to Cremophor El. SAAD Dig. 1981;9:209.
8. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007;119(2):197-206.
9. Bökenkamp A, Offner G, Hoyer PF, Vester U, Wonigeit K, Brodehl J. Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol. 1995;2:196-8.
10. Taylor NE, Mark AE, Vallat P, Brunne RM, Testa B, Van Gunteren WF. Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simula-tions. J Med Chem. 1993;24:3753-64.
11. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit. 1998;20(3):276-83.
12. Wang XQ, Dai JD, Chen Z, Zhang T, Xia GM, Nagai T, et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release. 2004;97(3):421-9.
13. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;11:1561-72.
14. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;13:1590-98.
15. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an In vitro study. J Natl Cancer Inst. 1997;4:300-6.
16. Utreja P, Jain S, Yadav S, Khandhuja KL, Tiwary AK. Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation. Curr Drug Saf. 2011;5:329-38.
17. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13-23.
18. Bowers LD. Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. Clin Biochem. 1991;1:81-7.
19. Sullivan PG, Sebastian AH, Hall ED. Therapeutic window analysis of the neuroprotective effects of cyclosporine a after traumatic brain injury. J Neurotrauma. 2011;2:311-8.
20. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;11:699-705.
21. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc. 2004;2(Suppl):229S-33S.
22. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-72.
23. Walstra P. Principles of emulsion formation. Chem Eng Sci. 1993;48(2):333-49.
24. Mueller E, Kovarik J, van Bree J, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994;11(2):301-4.
25. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003;92(12):2386-98.
26. Chiu Y-Y, Higaki K, Neudeck B, Barnett J, Welage L, Amidon G. Human jejunal permeability of cyclosporin a: influence of surfactants on P-glycoprotein efflux in caco-2 cells. Pharm Res. 2003;20(5):749-56.
27. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238-57.
28. Neale C, Ghanei H, Holyoake J, Bishop RE, Prive GG, Pomes R. Detergent-mediated protein aggregation. Chem Phys Lipids. 2013;169:72-84.
29. Nagarajan R. Amphiphilic surfactants and amphiphilic polymers: principles of molecular assembly. Amphiphiles: molecular assembly and applications. ACS Symposium Series. 1070: American Chemical Society; 2011; 1-22.
30. Dickinson E. Use of nanoparticles and microparticles in the formation and stabilization of food emulsions. Trends Food Sci Technol. 2012;24(1):4-12.
31. Frelichowska J, Bolzinger MA, Chevalier Y. Pickering emulsions with bare silica. Colloids Surf A Physicochem Eng Asp. 2009;343(1-3):70-4.
32. Destribats M, Ravaine S, Heroguez V, Leal-Calderon F, Schmitt V. Outstanding stability of poorly-protected pickering emulsions. Trends in colloid and interface science XXIII. Progress in Colloid and Polymer Science. 137: Springer Berlin Heidelberg; 2010. p. 13-8.
33. Lim LH, Tan A, Simovic S, Prestidge CA. Silica-lipid hybrid microcapsules: Influence of lipid and emulsifier type on in vitro performance. Int J Pharm. 2011;409(1-2):297-306.
34. Simovic S, Barnes TJ, Tan A, Prestidge CA. Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids. Nanoscale. 2012;4(4):1220-30.
35. Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm. 2010;7(2):522-32.
36. Simovic S, Prestidge CA. Nanoparticle layers controlling drug release from emulsions. Eur J Pharm Biopharm. 2007;67(1):39-47.
37. Capron I, Cathala B. Surfactant-free high internal phase emulsions stabilized by cellulose nanocrystals. Biomacromolecules. 2013 Feb 11;14(2):291-6.
38. Yuan JS, Acosta EJ. Extended release of lidocaine from linker-based lecithin microemulsions. Int J Pharm. 2009;368(1-2):63-71.
39. Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J Control Release. 2010;142(1):22-30.